Topical Betaxolol for the Prevention of Retinopathy of Prematurity
NCT ID: NCT01660620
Last Updated: 2013-01-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
23 participants
INTERVENTIONAL
2011-04-30
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity
NCT01993043
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
NCT00346814
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
NCT00622726
Bevacizumab Treatment For Type 1 ROP
NCT04634578
Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
NCT02390531
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
betaxolol
betaxolol 0.25% 2 per day for 3 weeks
Betaxolol
placebo
masked labeling also 2 per day administration
topical betaxolol
given topically
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Betaxolol
topical betaxolol
given topically
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
32 Weeks
32 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ohio State University
OTHER
University of Minnesota
OTHER
University of Oklahoma
OTHER
The University of Texas Health Science Center, Houston
OTHER
Smith-Kettlewell Eye Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
William V Good, MD
Administrator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
108298
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.